ME/CFS(6 expert discussions analyzed)

ME/CFS is a long-term illness whose defining feature is post-exertional malaise: symptoms that worsen hours to days after physical or mental effort. There is no cure yet. The most established practical approach is managing activity within your energy limits, which the UK's NICE guideline also recommends. Research into autoantibodies, repurposed drugs and immune-cell treatments is active, especially at the Charité in Berlin, but most of it is still at an early stage.

First synthesised Jun 9, 2026·Last reviewed Oct 6, 2026

289 min of expert content · 14 min read|Summary:|

What matters

Primary Topic Intent

Help readers with ME/CFS understand what is established (pacing and energy management, and avoiding fixed increases in exercise), what is still being tested (off-label drugs and autoantibody-targeted treatments), how ME/CFS overlaps with Long COVID, and what to discuss with a specialist.

Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME/CFS) is a complex multi-system illness whose leading clinical feature is post-exertional malaise (PEM) — a worsening of all symptoms hours to days after physical or cognitive exertion. ME/CFS frequently arises after viral infections, with Epstein-Barr virus (EBV / mononucleosis) historically the most studied trigger and COVID-19 now driving a substantial new patient population. No definitive biomarker exists; diagnosis uses symptom-criteria catalogues such as the Canadian Consensus Criteria, the Institute of Medicine (IOM) criteria, or the International Consensus Criteria for ME. The disease has long been under-recognized in clinical care, often dismissed as functional or psychosomatic, a framing the sources on this page reject.

Research suggests ME/CFS may involve several biological mechanisms that differ between patients. In one subset, Scheibenbogen's group at the Charité has found raised autoantibodies against beta-2 adrenergic receptors, which they think may drive autonomic and circulatory symptoms. In a Charité study of patients selected for these antibodies, Scheibenbogen reports that immunoadsorption (temporarily clearing antibodies from the blood) improved symptoms in about three in four, but the effect did not last; she describes it as a bridge, not a cure. Those who responded shared a pattern in their antibody-producing B cells, which the team now plans to use to select patients for trials. These are research findings from one centre: autoantibody testing is not standard care and does not yet guide treatment.

Scheibenbogen notes that for most medicines used off-label in ME/CFS, the only evidence comes from small studies, case reports or uncontrolled studies. A German expert commission, working mainly on Long COVID, proposed five medicines for off-label reimbursement where it judged the data may be sufficient: agomelatine and low-dose naltrexone (LDN) for fatigue, vortioxetine for cognitive symptoms, ivabradine for a fast heart rate, and metformin to prevent Long COVID. Agomelatine had been studied in ME/CFS; the LDN studies were in Long COVID, and the commission did not extend LDN to ME/CFS. The reimbursement decision was pending at the time of her talk. NICE NG206 advises that no medicine or supplement should be offered as a cure for ME/CFS. As context from Long COVID research only: Scheibenbogen describes a large controlled trial (Bramante 2023, not reviewed directly for this page) in which taking metformin within seven days of a COVID infection reduced the risk of Long COVID. That concerns preventing Long COVID during acute infection, not treating ME/CFS, and belongs to the COVID-19 & Long COVID Topic.

The next research step at the Charité is to test whether removing the B cells or plasma cells that produce antibodies gives lasting benefit in patients with this immune profile. Three approaches (targeting CD19, CD20 and CD38) are planned; at the time of the talk, only the CD38 study had funding. No results are available yet, so these are research directions, not treatment options.

Across all subtypes and research directions, pacing remains the most reliable practical principle: doing just enough each day to avoid the delayed energy crash that defines post-exertional malaise. Specialist clinics (including university-affiliated post-viral illness clinics) adapt rehabilitation accordingly. Some people with ME/CFS are still advised to follow graded exercise therapy, meaning step-by-step increases in activity on a fixed schedule. In 2021 the UK's NICE guideline (NG206), which replaced its 2007 guideline that had included graded exercise therapy, advised against this and against any programme with fixed increases, because it may make symptoms worse. Instead it recommends managing energy within each person's limits, with activity adjusted up only after a stable period and down when symptoms worsen. Knowing which type of clinical setting you are in is itself a practical decision lever for patients and family members. If a reader takes only one practical lesson from this page, it should be this: avoid triggering post-exertional malaise through pacing. Questions about off-label medicines and research trials all sit on top of that foundation; pacing is what protects you while the rest of the picture clarifies.

Best-supported action

If you have ME/CFS, or symptoms that worsen hours to days after effort, manage your activity within your energy limits (pacing), and avoid programmes that increase exercise on a fixed schedule.

Pacing does not cure ME/CFS, and it is not the same as avoiding all activity. Off-label medicines, autoantibody research and immune-cell trials may become relevant, but they rest on small studies or are still being tested; discuss them with a specialist rather than starting from them.

Sources: 6 expert episodes · See sources

Understand where experts converge, where they differ, and what remains uncertain.

What we still don't know

This does not prove that any of the five proposed off-label drugs will cure ME/CFS; they aim at symptom relief while research advances toward potentially disease-modifying treatments.

This does not prove that autoantibody-driven ME/CFS represents the majority of cases; subtype proportions remain under active study and the field increasingly recognizes distinct subtypes that may need different treatments.

B-cell depletion trials at the Charité are still pending results. Whether removing antibody-producing cells produces lasting benefit, and which cell-surface targets (CD19, CD20, CD38) prove most effective, are open questions.

The LDN studies Scheibenbogen cites were conducted in Long COVID, not ME/CFS, and the immunoadsorption result comes from one centre; neither was reviewed directly for this page.

Metformin's effect on Long COVID risk is reported in the Bramante 2023 trial and its follow-up, as described by Scheibenbogen; the trial was not reviewed directly for this page, and the precise mechanism remains under investigation. The time window matters: earlier is better, with the strongest effect when started within 3 days of acute COVID symptoms.

Pacing as a treatment principle is well-supported clinically but has limited large randomized trial confirmation as a standardized intervention. NICE bases its recommendation on its review of the evidence and the committee's experience. The principle is reasonable; the specific implementation varies by patient.

Off-label prescribing varies substantially by country. The German G-BA approval process is country-specific; US, UK, Canadian, and Australian patients face different regulatory paths to access the proposed five-drug list, and many drugs are already used off-label without formal approval. Discuss with a clinician familiar with the regulatory landscape in your country.

This page is positioned as a Disease Topic with links to the Long COVID Topic, given overlapping biological features under investigation. Some content (mechanism subtypes, pacing, combination therapy framing) is shared between the two Topics. Cross-channel sourcing limitation: research consensus is heavily weighted toward Germany (Charité) and US / UK Long COVID research; ME/CFS-specific centers in other countries (Bateman Horne in the US, Newcastle in the UK, others) would strengthen the synthesis further.

This does not mean you should change or stop any current medical treatment on your own.